Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine if additional panretinal photocoagulation of ischemic areas following retinal vein occlusion (RVO) may reduce the rate of recurrence and allow longer treatment intervals in anti-Vascular Endothelial Growth Factor (VEGF) treatment following the "trea-and-extend" scheme.


Clinical Trial Description

Patients with macular edema following RVO receive an anti-VEGF treatment by injection of Ranibizumab for 12 months in the "treat-and-extend" scheme. Following this scheme, all patients receive a series of three injections at the interval of 4 weeks. Thereafter, the retreatment interval is determined by results of certain examinations.

The next control including a reinjection is scheduled with an extension of one week until the patient presents signs of recurrence. Assuming that by the time of recurrence the interval is too long, the next control (following a retreatment) is then scheduled one week sooner than the last control. Following this treatment schedule, the individualized retreatment interval is thereafter kept steady.

Half the patients receive an additional panretinal photocoagulation on visit 3 and / or 4. Aim of this study is to investigate if this additional panretinal photocoagulation may result in a longer individualized retreatment interval corresponding to a reduced rate of recurrence of macular edema. ;


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02522897
Study type Interventional
Source Ludwig-Maximilians - University of Munich
Contact Verena Dykstra, Dr.
Phone +49 228 287 16360
Email verena.dykstra@ukb.uni-bonn.de
Status Not yet recruiting
Phase Phase 4
Start date August 2015
Completion date January 2018

See also
  Status Clinical Trial Phase
Completed NCT02556723 - Intravitreal Injections of Ziv-aflibercept for Macular Diseases N/A
Completed NCT02006147 - Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO Phase 1/Phase 2
Completed NCT05832996 - Cool vs Room-temperature Artificial Tears Phase 4
Completed NCT04812977 - Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion N/A
Completed NCT04290195 - Use of Ziv Aflibercept in Different Retinal Diseases Phase 1/Phase 2
Recruiting NCT04444492 - Combination of Ranibizumab and Targeted Laser Photocoagulation Phase 3